Evolus, Inc. (EOLS) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2025. Evolus, Inc. is a global performance beauty company operating in the cash-pay aesthetic market. Its portfolio consists of Jeuveau (a botulinum toxin type A neurotoxin) and Evolysse (a collection of injectable hyaluronic acid gels). In April 2025, the company launched Evolysse Form and Smooth in the United States. The company relies on third-party manufacturers, Daewoong (for Jeuveau) and Symatese (for Evolysse), for production.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Net Revenues | $297,176 | $266,274 |
| Gross Profit | $197,107 | $182,304 |
| Gross Margin | 66.3% | 68.5% |
| Net Loss | $(51,641) | $(50,420) |
| Operating Cash Flow | $(42,265) | $(17,999) |
| Cash and Cash Equivalents (Year End) | $53,826 | $86,952 |
| Total Debt (Principal) | $150,000 | $125,000 |
| Stockholders' Equity (Deficit) | $(23,106) | $5,522 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 11.6% to $297.2 million, driven by the U.S. launch of Evolysse and continued growth in Jeuveau sales.
- Margin Compression: Gross margin decreased from 68.5% to 66.3%, attributed to product mix changes and promotional programs.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 11.5% to $220.8 million due to personnel costs associated with the Evolysse launch. Restructuring costs of $1.4 million were incurred in 2025 for cost optimization.
- Debt Structure: In May 2025, the company amended its term loan agreement with Pharmakon, increasing the principal to $150 million. In March 2026 (subsequent event), a $30 million revolving credit facility was secured.
- Equity Position: The company moved from positive equity in 2024 to a stockholders' deficit of $23.1 million in 2025 due to the net loss and accumulated deficit.
Outlook, Risks, and Management Commentary
- Product Pipeline: The company expects to launch all four Evolysse products in Europe in Q2 2026. PMA approval for Evolysse Sculpt is expected in the second half of 2026, with Evolysse Lips anticipated in 2027.
- Liquidity: Management believes current cash resources, operating cash flow, and available debt facilities are sufficient to fund operations for at least the next 12 months.
- Key Risks:
- Regulatory Dependence: Reliance on Symatese for U.S. regulatory approval of the Evolysse line.
- Trade Policy: Exposure to tariffs on imports from South Korea (Jeuveau) and France (Evolysse), which could increase costs.
- Competition: Intense competition in the aesthetic neurotoxin and dermal filler markets from larger competitors with greater resources.
- Profitability: The company has incurred losses since inception and faces ongoing royalty obligations to Medytox and Evolus Founders that impact profitability.
Investor Verification Checklist
- Regulatory Milestones: Verify the timeline for FDA approval of Evolysse Sculpt and Lips, as delays could impact future revenue projections.
- Tariff Impact: Monitor U.S. trade policy changes regarding pharmaceuticals and medical devices from South Korea and France to assess potential margin erosion.
- Liquidity Runway: Confirm the utilization of the new $30 million revolving credit facility and the company's ability to meet minimum purchase obligations under licensing agreements.
- Contingent Liabilities: Review the fair value assumptions for the contingent royalty obligation to Evolus Founders, which fluctuates based on revenue forecasts.
- Market Adoption: Assess early sales data for Evolysse Form and Smooth in the U.S. to gauge market acceptance against established competitors.